Business & Technology News » Blog Archive » CHMP Recommends Approval of Lilly and Incyte’s OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)

20 May 2022

CHMP Recommends Approval of Lilly and Incyte’s OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)

Author: admintech | Filed under: Press Release

INDIANAPOLIS, May 20, 2022 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for OLUMIANT® (baricitinib) for the…

This entry was posted on Friday, May 20th, 2022 at 7:16 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

CHMP Recommends Approval of Lilly and Incyte’s OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)

Categories